What is NephroPlus?
NephroPlus stands as India's largest dialysis provider network, dedicated to delivering high-quality dialysis services with a primary focus on patient care and comfort. The company has been instrumental in reshaping perceptions around dialysis, emphasizing its potential to be a less stressful experience for patients. Through its extensive network and commitment to quality, NephroPlus aims to make advanced dialysis care accessible and less burdensome for a growing patient population across India.
How much funding has NephroPlus raised?
NephroPlus has raised a total of $155.1M across 5 funding rounds:
Series A
$4.3M
Series B
$10M
Series C
$15M
Series E
$24M
Series F
$101.8M
Series A (2011): $4.3M with participation from Bessemer Venture Partners
Series B (2014): $10M led by Bessemer Venture Partners and International Finance Corporation
Series C (2016): $15M supported by SeaLink Capital Partners and International Finance Corp
Series E (2021): $24M featuring Bessemer Venture Partners, Investcorp, and IIFL Asset Management
Series F (2024): $101.8M backed by Quadria Capital Investment Management
Key Investors in NephroPlus
Quadria Capital Investment Management
Quadria Capital is a leading private equity firm focused on transforming healthcare in Asia through strategic investments in scalable healthcare companies. They emphasize partnerships with organizations that have strong management teams and clear market differentiation.
Bessemer Venture Partners
Bessemer Venture Partners is a venture capital firm with a long history, investing across various stages and geographies, known for its support of technology and healthcare companies.
Investcorp
Investcorp is a global alternative investment manager focusing on private equity, real estate, and credit management, with a strategy to invest in businesses that offer significant growth potential.
What's next for NephroPlus?
The recent major strategic investment in NephroPlus signals a new phase of expansion and potential service diversification. With a history of significant capital raises, including a Series E round and now a Series F, the company is well-positioned to further solidify its leadership in the Indian dialysis market. Future endeavors are likely to involve scaling its network, enhancing technological integration for better patient management, and potentially exploring adjacent healthcare services to complement its core dialysis offerings. This strategic backing will be crucial for navigating the evolving healthcare landscape and meeting the increasing demand for quality renal care.
See full NephroPlus company page
